Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not if it happens... But "when it happens".
Relax... This isn't a new PR, this is the original PR from the first time the 6 month results for Angel phase 1 were release. However, we should be getting a new PR with the full results soon as today is the day the presents the 6 month results in its entirety.
http://www.marketwired.com/press-release/bioheart-inc-present-clinical-trial-results-age-management-medicine-group-conference-otcqb-bhrt-1901473.htm
100% just like the existence of BioHeart is also 100%.
Already on it. Specially at these levels.
The inevitable is near DDLS. All it takes is the appropriate situation to open the flood gates that will not be able to hold back the pps. IMO.
Here's your update Hop. On March 26, 2014
"Our product, MyoCell, has been the subject of nearly a dozen peer reviewed journal articles and has been reported on by many prominent speakers. The results of the MARVEL trial speak for themselves. In the double blind placebo controlled MARVEL trial, myoblast treated patients increased in exercise capacity by 95.6 meters while control patients declined by 3.6 meters after 6 months. This is double the improvement that was reported by others in autologous bone marrow and cardiac stem cells trials and more than eight times better than results published in allogeneic bone marrow studies. We are continuing to study this therapy in double blind placebo trials including MARVEL part 2 and MIRROR. We intend to continue the placebo trials including MARVEL part 2 and MIRROR—and continued enrollment in placebo trials including MARVEL part 2 and MIRROR studies is dependent on obtaining the necessary funding. Because they are double blind placebo controlled studies, results will only be presented after enrollment is complete."
And please keep in mind...
"We intend to continue the placebo trials including MARVEL part 2 and MIRROR—and continued enrollment in placebo trials including MARVEL part 2 and MIRROR studies is dependent on obtaining the necessary funding. Because they are double blind placebo controlled studies, results will only be presented after enrollment is complete."
http://stemcellceo.com/wp/bioheart/bioheart-cso-review/
This tells me the trial is ongoing, not forgotten... Once enrollment is complete, I hope you don't disappear on us so that we can continue to discuss the great things this company will bring to mankind.
Funding will be made available if not already... There is no way this company could continue to operate in the fashion it has been with all the new developments if that wasn't the case. IMO.
Tomorrow BioHeart presents the full results of the 6 month end point for Angel phase 1.
http://www.bioheartinc.com/assets/press/BIOHEART,INC.TOPRESENTCLINICALTRIALRESULTS.pdf
I wholeheartedly agree with you on the placebo effect. I believe BioHeart, for this reason, collects data at 3 6 and 12 months. This is due to the 3 month data collection often having placebo effects in it. What BioHeart sees is that after the 6 and 12 month data collection of the original injections... The placebo effect no longer is a factor and those who were actually treated perform as expected with significant improvements.
Furthermore, I too am excited about the fact that they are materializing concrete visible scientific evidence with state of the art equipment that is proving the positive effects of stem cell injections to the heart.
Now I have heard K. Comella mention mesenchymal cells during her webinars. I'll have to look into what exactly BioHeart is using these cells for.
Thanks for your unbiased response.
Here's a good read about stem cell injections via catheter to the heart.
http://www.healthcanal.com/blood-heart-circulation/heart-disease/50094-two-new-miller-school-studies-show-how-stem-cell-injections-improve-heart-structure.html
Aside from attending the event live I don't believe there is any other way to listen in as it occurs or immediately after. I take it any significant news will come with a PR the morning of, after the conference, or lastly the morning after.
Doesn't matter right now or for a nice amount of years as any competition for the exact treatment would have to take the long clinical trial road for a long period of years. IMO
The darkest hour is just before the dawn.
There it is. So we present Thursday and Friday. GLTA
Any news on the SelectBio presentation from yesterday??
http://online.wsj.com/article/PR-CO-20140402-906436.html
Yes they did get the green light a few months back. You are 100% in your forward looking statement for revenues in stem cell banking as well as for BioHeart positioning itself to capitalize on the revenues pertaining to stem cell banking.
Why thank you chuck. Without tooting my own horn, I must agree with you.
Look what I just received in my inbox.
Three new wibinars
STEM CELL BANKING
REGISTER TODAY!
April 29, 2014 at 7:00 PM EST
Bioheart's Stem Cell Banking - an additional service for
your patients and an additional revenue stream for you!
How can I provide long term stem cell options to my patients?
How does stem cell banking work?
How long can my patients bank their stem cells for?
What type of stem cells can my patients bank?
REGISTER TODAY!
JOURNAL CLUB
April 30, 2014 at 12:00 PM EST
Article Title: Comparison of Platelet-Rich Plasma Formulations for Cartilage Healing - An in Vitro Study
Partake in a discussion with the industry expert, Kristin Comella,
to discuss this study's investigation on the effect of various PRP formulations on human chondrocytes in vitro.
Download the article here.
REGISTER TODAY!
STEM CELL THERAPY REGULATIONS
May 6, 2014 at 12:00 PM EST
Learn about the current regulatory environment and how to safely, legally and ethically offer patients adult stem cell treatments in your practice.
What are the current Adult Stem Cell (ASC) ethics & policies?
What are the current regulations on advanced cell therapies?
What is the FDA's involvement?
What are the current stem cell clinical trials?
Panel Discussion: Strategic Partnering
Brock Reeve, Executive Director, Harvard Stem Cell Institute
Edward Lanphier, President & Chief Executive Officer, Sangamo Biosciences
Matthew Vincent, Director of Business Development, Advanced Cell Technology
http://www.gtcbio.com/conference/stem-cell-summit-agenda
SA is a POS website that should not be taken seriously. "Reports" are very biased and IMO have hidden agendas.
You're not alone!! Long and strong, battling through the stormy seas in search for dry land!!
Our focus is the companies advancement towards commercialization as well as the well being of mankind, not the share price currently. The share price will fall into place as we approach our goals. The inevitable will occur DDLS. I hope you're still around to discuss our success when it occurs rather than choosing to fallback out of sight.
Rabin?? Don't dwell in the past... Follow us into the inevitable future!!
Stem-Cell Treatment for Blindness Moving Through Patient Testing
http://www.technologyreview.com/news/526591/stem-cell-treatment-for-blindness-moving-through-patient-testing/
Haha, no disrespect intended... Just looking for clarification. Hey on a side note, two dates next week (21, and 25) should be exciting for BioHeart as we continue to increase awareness of the company and it's trials?
Nice, but what of the "change" on the BioHeart website? What change?
I don't understand your question... Can you rephrase please?
"A new therapy and the first of its kind, based on embryonic cells to cure vision loss were launched this year by Advanced Cell Technology."
This year?
I understand but it was positioned as if treatment began this year?
Can you guys please tell me what you think about this confusing report? Thank
http://www.newsonwellness.com/2014/04/new-stem-cell-therapy-macular-degeneration-testing-among-patients/
Man there's a lot covered in this report, as I'm going over it I read that they began seeing revenues for Adipocell last year.
Sounds like the footsteps of financing approaching our doorstep!
Your absolutely correct as to that being the only reason. I too was searching for the "why behind the why" and that's also what I came up with. Looks like preparation for financing.
Contrary to the volume you speak of... There now seems to be a larger volume of optimistic events going on with ACTC... Stick around DDLS so that you may witness the inevitable, completion of phase 1, TLD, and the start of phase 2
Well here's a report that begs to differ with your "shelving" theory.
http://www.technologyreview.com/news/526591/stem-cell-treatment-for-blindness-moving-through-patient-testing/
Also, the publication has a lot to do with the company as a whole.
This email is compliments of Scottrade.com
If you would like to modify or suspend this alert, please login to your Scottrade account and navigate to the "Alerts" page under the "My Account" tab.
News for 'ACTC' - (DJ Scientists Make First Embryo Clones From Adults)
By Gautam Naik
Scientists for the first time have cloned cells from two adults to create early-stage embryos, and then derived tissue from those embryos that perfectly matched the DNA of the donors.
The experiment represents another advance in the quest to make tissue in the laboratory that could treat a range of maladies, from heart attacks to Alzheimer's. The study, involving a 35-year-old man and one age 75, was published Thursday in the journal Cell Stem Cell.
The creation of the first early-stage human clones, using infant and fetal cells rather than those from adults, was reported last year. The new experiment, with a few tweaks, confirms that striking and controversial breakthrough and also shows the technique works on mature cells.
"The proportion of diseases you can treat with [lab-made tissue] increases with age. So if you can't do this with adult cells, it is of limited value," said Robert Lanza, co-author of the study and chief scientific officer at Advanced Cell Technology Inc. of Marlborough, Mass. The study was funded by the government of Korea and done at a lab in California.
Such experiments are controversial because when cells are extracted from an early-stage human embryo, it destroys the embryo, which some people believe is equivalent to taking a life.
And while the embryos created in these recent experiments may have certain limitations that would prevent them from giving rise to a human clone even if implanted in a womb, that prospect is now scientifically closer.
As with the 2013 experiment, done by researchers at the Oregon Health and Science University, Dr. Lanza and his colleagues first extracted the DNA from an unfertilized human egg and replaced it with the DNA from one of the older donors. The egg automatically "reprogrammed" its DNA until it reached a stage of the embryo known as a blastocyst--a hollow ball of 50 to 100 cells.
Cells from the blastocyst then were cultured in a lab dish and yielded stem cells that were an exact match to the donor's DNA. Those stem cells subsequently were turned into other tissue types, such as heart cells, which potentially could be transplanted into the patient without triggering an immune rejection.
"I'm happy to hear that our experiment was verified and shown to be genuine," said Shoukhrat Mitalipov, a development biologist at Oregon Health and Science University, in Portland, Ore., who led the 2013 study that Dr. Lanza and his colleagues have now replicated.
Despite this advance, experts say it wouldn't be easy to create a full-fledged human clone. Scientists have been trying for years to clone monkeys and have yet to succeed. Even the cloning of less-complicated creatures--from sheep to rabbits and dogs--required years of tweaking, and lots of wasted eggs and deformed fetuses, before it worked.
The recent experiments, nonetheless, have some observers worried. Dozens of countries have laws explicitly banning human reproductive cloning, though there is no equivalent federal law in the U.S. Most U.S. states don't have such laws either, though a few, such as California, do.
"If we're closer to some rogue scientist or fertility doctor using published techniques to create cloned humans, it certainly ups the stakes and means we should be moving to put a federal law in place," said Marcy Darnovsky, executive director of the Center for Genetics and Society, a nonprofit public interest group in Berkeley, Calif.
Write to Gautam Naik at gautam.naik@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
April 17, 2014 12:13 ET (16:13 GMT)
Copyright (c) 2014 Dow Jones & Company, Inc.- - 12 13 PM EDT 04-17-14
Source: DJ Broad Tape